A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Fiche publication
Date publication
octobre 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MAYEUR Didier
Tous les auteurs :
Zelek L, Debourdeau P, Bourgeois H, Wagner JP, Brocard F, Lefeuvre-Plesse C, Chauffert B, Leheurteur M, Bachet JB, Simon H, Mayeur D, Scotté F
Lien Pubmed
Résumé
Neurokinin (NK) 1 receptor antagonists (RAs), administered in combination with a 5-hydroxytryptamine-3 (5-HT ) RA and dexamethasone (DEX), have demonstrated clear improvements in chemotherapy-induced nausea and vomiting (CINV) prevention over a 5-HT RA plus DEX. However, studies comparing the NK RAs in the class are lacking. A fixed combination of a highly selective NK RA, netupitant, and the 5-HT RA, palonosetron (NEPA), simultaneously targets two critical antiemetic pathways, thereby offering a simple convenient antiemetic with long-lasting protection from CINV. This study is the first head-to-head NK RA comparative study in patients receiving anthracycline cyclophosphamide (AC) and non-AC moderately emetogenic chemotherapy (MEC).
Mots clés
Chemotherapy-induced nausea and vomiting • Netupitant • Palonosetron • Aprepitant • NEPA
Référence
Oncologist. 2021 10;26(10):e1870-e1879